Newsquawk Logo

Merck's (MRK) KEYTRUDA plus paclitaxel with or without bevacizumab is the first PD-1 inhibitor-based regimen to show a statistically significant improvement in OS regardless of PD-L1 status

Merck's announcement regarding KEYTRUDA is significant as it demonstrates a breakthrough in cancer treatment, potentially enhancing their competitive position in the oncology market.

Newsquawk StaffPublished On the live feed at — 3 more headlines followed before this page went public
Newsquawk headlinesUTC

US State Department says Secretary of State Rubio will travel to Israel from March 2-3, will discuss Iran, Lebanon and Gaza

US official denies news of evacuation of US embassy staff in Baghdad, via Al Arabiya

Merck's (MRK) KEYTRUDA plus paclitaxel with or without bevacizumab is the first PD-1 inhibitor-based regimen to show a statistically significant improvement in OS regardless of PD-L1 status

Merck (MRK) reportedly cutting workforce at the Gardasil plant, citing falling global demand, according to reports

China’s coordinated policies, full industrial system, and vast domestic market are expected to deliver steady, high-quality growth and a strong start to the 15th Five-Year Plan, Global Times reports

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
Context

The statistically significant improvement in overall survival (OS) regardless of PD-L1 status could lead to expanding the drug's application, positively impacting future revenues and market perception of Merck's capabilities in pharmaceuticals. Investors should assess how this news influences Merck’s stock performance and broader sector sentiment.

External

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.